Skip to main content
Michael Goggins, MD, Gastroenterology, Baltimore, MD, Johns Hopkins Hospital

MichaelGilbertGogginsMD

Gastroenterology Baltimore, MD

Pancreas Disease

Professor of Pathology, Professor of Medicine, Professor of Oncology, Johns Hopkins University School of Medicine;

Dr. Goggins is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Goggins' full profile

Already have an account?

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Gastroenterology, 1999 - 2000
  • University of Dublin Trinity College
    University of Dublin Trinity CollegeClass of 1988

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 2001 - 2024

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2009-2018
  • America's Top Doctors for Cancer Castle Connolly, 2005-2018
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Pancreatic Cancer Arising in the Remnant Pancreas Is Not Always a Relapse of the Preceding Primary  
    John L Cameron, Christopher L Wolfgang, Jin He, Matthew J Weiss, Ralph H Hruban, Michael Goggins, Nature
  • Single‐Cell Sequencing Defines Genetic Heterogeneity in Pancreatic Cancer Precursor Lesions  
    Kevin Waters, Jin He, Christopher L Wolfgang, Ralph H Hruban, Michael G Goggins, Matthew J Weiss, Justin Poling, The Journal of Pathology
  • Primordial Germ Cells as a Potential Shared Cell of Origin for Mucinous Cystic Neoplasms of the Pancreas and Mucinous Ovarian Tumors  
    Leona A Doyle, Daniel W Cramer, Michael Goggins, Ronny Drapkin, Jason L Hornick, Kevin M Elias, Michael Birrer, Michelle S Hirsch, The Journal of Pathology
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Lectures

  • Improving the early detection of pancreatic cancer. 
    Johns Hopkins Oncology Center - 2/19/2014
  • The potential clinical utility of markers of pancreatic neoplasia. 
    Yale, New Haven, CT - 11/22/2013
  • "The potential clinical utility of markers of pancreatic neoplasia", Visiting Professor 
    University of Pennsylvania, Philadelphia - 11/13/2013
  • Join now to see all

Other

  • Absence of ALK-5 mutations in breast cancer cell lines. 
    Goggins M, Shekher M, Turnacioglu K, Yeo CJ, Hruban RH, Kern SE, NOgO
    1/1/1998
  • Absence of Beta-catenin mutations in patients with pancreatic cancer. ( On-Line Publication) 
    Goggins M, Hilgers W, Hruban RH, Kern SE, NOgO
    1/1/1997
  • Absence of Beta-catenin mutations in patients with breast cancer. 
    Goggins M, Hilgers W, Hruban RH, Kern SE, NOgO
    1/1/1997
  • Join now to see all

Authored Content

  • Q&A: Early Pancreatic Cancer Diagnoses Provide Best Chance for Long-Term SurvivalNovember 2018
  • Q&A: Early Pancreatic Cancer Diagnoses Provide Best Chance for Long-Term SurvivalNovember 2018

Press Mentions

  • ACVR1C/SMAD2 Signaling Promotes Invasion and Growth in Retinoblastoma
    ACVR1C/SMAD2 Signaling Promotes Invasion and Growth in RetinoblastomaNovember 6th, 2018
  • BU Researcher Leads Team in ‘Cancer Interception’ Project
    BU Researcher Leads Team in ‘Cancer Interception’ ProjectNovember 7th, 2017
  • Dream Team Plans to Stop Pancreatic Cancer Before Symptoms Occur
    Dream Team Plans to Stop Pancreatic Cancer Before Symptoms OccurOctober 26th, 2017
  • Join now to see all

Grant Support

  • Using Markers to Improve Pancreatic Cancer ScreeningNIH2013–Present
  • Screening for pancreatic neoplasia, the CAPS5 studyAACR-Pancan2013–Present
  • Screening markers for high pancreatic cancer susceptibilityNIH2012–Present
  • Intercepting pancreatic cancer in high-risk cohortsStand Up to Cancer2018–2022
  • Using markers to improve pancreatic cancer screening and surveillanceNCI2016–2021
  • Screening Markers For Persons With High Pancreatic Cancer SusceptibilityNational Cancer Institute2007–2011
  • Predicting Pancreatic Cancer Responses For A PARP Inhibitor-Based Clinical TrialNational Cancer Institute2009–2010
  • Markers Of Early Pancreatic CancerNational Cancer Institute2006–2010
  • Classifying Pancreatic Cancers By Methylator PhenotypesNational Cancer Institute2003–2006
  • Screening Markers For High Pancreatic CancerNational Cancer Institute2002
  • The Panins Of Pancreatitis,Pancreas Cancer And ControlsNational Cancer Institute2001–2002
  • Folate Pathway Polymorphisms And Pancreatic Cancer RiskNational Cancer Institute2001–2002

Professional Memberships

Hospital Affiliations